GlassScriptPhysician profile
Stephan Michael Moss
NPI 1063906857
$4,429.50
in general payments reported to CMS, 2019-2025
31 companies · $861 in 2025
The $861 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $709 · 2022: $775 · 2023: $1,121 · 2024: $964 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,118.00 | 2021-2025 | |
| Amgen INC. | $481.35 | 2023-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $344.35 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $278.10 | 2021-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.94 | 2024-2025 | Caplyta |
| Organon LLC | $103.40 | 2021-2025 | Nexplanon, Nuvaring |
| Amarin Pharma, INC. | $89.90 | 2021-2022 | |
| Astellas Pharma US INC | $81.34 | 2023-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $76.80 | 2022 | |
| Pfizer INC. | $73.36 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $69.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $66.36 | 2023 | |
| Nestle Healthcare Nutrition INC. | $65.14 | 2021-2022 | |
| Lilly USA, LLC | $64.35 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $54.86 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $40.23 | 2024 | Trelegy Ellipta |
| Abbott Laboratories | $38.43 | 2023-2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $33.94 | 2022 | |
| Lucid Diagnostics INC. | $27.03 | 2022 | |
| Axsome Therapeutics, INC. | $26.95 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $25.79 | 2022 | |
| Edwards Lifesciences Corporation | $23.91 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Becton, Dickinson and Company | $19.56 | 2024 | Bd Onclarity |
| Inspire Medical Systems, INC. | $18.30 | 2023 | Inspire |
| Esperion Therapeutics, INC. | $15.49 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.87 | 2025 | |
| Sunovion Pharmaceuticals INC. | $13.69 | 2021 | |
| Lundbeck LLC | $13.56 | 2025 | Rexulti |
| Medtronic, INC. | $13.53 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.32 | 2023 | |
| Merck Sharp & Dohme LLC | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.